Intercept Pharmaceuticals (NASDAQ:ICPT) Lowered to Strong Sell at BidaskClub

BidaskClub lowered shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a sell rating to a strong sell rating in a research note issued to investors on Wednesday, June 26th, BidAskClub reports.

Several other research analysts also recently commented on the company. Stifel Nicolaus started coverage on Madrigal Pharmaceuticals in a research note on Monday, June 24th. They issued a hold rating and a $126.00 target price for the company. Cantor Fitzgerald set a $57.00 price objective on Apellis Pharmaceuticals and gave the company a buy rating in a report on Thursday, February 28th. Oppenheimer raised their price objective on Lendingtree from $350.00 to $440.00 and gave the company an outperform rating in a report on Monday, April 29th. Cowen reissued a buy rating and set a $149.00 price objective on shares of Intercept Pharmaceuticals in a report on Wednesday, May 8th. Finally, Royal Bank of Canada set a $20.00 price objective on BMC Stock and gave the company a hold rating in a report on Friday, March 1st. Four analysts have rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $142.00.

NASDAQ ICPT traded up $1.92 on Wednesday, reaching $71.67. The company had a trading volume of 755,081 shares, compared to its average volume of 873,229. The stock has a market capitalization of $2.08 billion, a PE ratio of -6.60 and a beta of 1.33. The company has a quick ratio of 3.72, a current ratio of 3.72 and a debt-to-equity ratio of 19.41. The business has a fifty day moving average price of $79.30. Intercept Pharmaceuticals has a 52-week low of $68.19 and a 52-week high of $133.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($3.03) earnings per share for the quarter, missing the consensus estimate of ($2.57) by ($0.46). Intercept Pharmaceuticals had a negative return on equity of 617.23% and a negative net margin of 162.49%. The firm had revenue of $52.25 million for the quarter, compared to the consensus estimate of $52.15 million. During the same quarter in the previous year, the company posted ($3.22) EPS. The firm’s revenue was up 45.3% compared to the same quarter last year. Sell-side analysts predict that Intercept Pharmaceuticals will post -10.1 earnings per share for the current fiscal year.

In related news, insider David Shapiro sold 2,000 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $86.28, for a total value of $172,560.00. Following the transaction, the insider now owns 41,499 shares of the company’s stock, valued at $3,580,533.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Lisa Bright sold 595 shares of the stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $78.66, for a total value of $46,802.70. Following the completion of the transaction, the insider now directly owns 20,452 shares in the company, valued at approximately $1,608,754.32. The disclosure for this sale can be found here. Corporate insiders own 5.00% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC increased its position in shares of Intercept Pharmaceuticals by 3.6% during the fourth quarter. Squarepoint Ops LLC now owns 3,399 shares of the biopharmaceutical company’s stock worth $343,000 after acquiring an additional 118 shares during the period. Hanseatic Management Services Inc. boosted its stake in Intercept Pharmaceuticals by 12.1% in the first quarter. Hanseatic Management Services Inc. now owns 2,077 shares of the biopharmaceutical company’s stock valued at $232,000 after acquiring an additional 224 shares in the last quarter. LPL Financial LLC boosted its stake in Intercept Pharmaceuticals by 0.3% in the fourth quarter. LPL Financial LLC now owns 74,815 shares of the biopharmaceutical company’s stock valued at $7,541,000 after acquiring an additional 254 shares in the last quarter. Advisor Group Inc. boosted its stake in Intercept Pharmaceuticals by 63.5% in the fourth quarter. Advisor Group Inc. now owns 739 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 287 shares in the last quarter. Finally, Financial Gravity Wealth Inc. acquired a new position in Intercept Pharmaceuticals in the first quarter valued at $33,000. 76.20% of the stock is owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Read More: What is a management fee?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.